Scarica l'app Stockscreener
5.68
1.97%
0.11
Dopo l'orario di chiusura:
5.70
0.02
+0.35%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.57
Aprire:
$5.64
Volume 24 ore:
503.39K
Relative Volume:
0.39
Capitalizzazione di mercato:
$252.80M
Reddito:
$3.64M
Utile/perdita netta:
$-87.37M
Rapporto P/E:
-1.382
EPS:
-4.11
Flusso di cassa netto:
$-86.46M
1 W Prestazione:
-4.86%
1M Prestazione:
+5.38%
6M Prestazione:
+127.20%
1 anno Prestazione:
-53.93%
Intervallo 1D:
$5.545
$5.87
Intervallo di 1 settimana:
$5.48
$6.03
Portata 52W:
$2.10
$13.82
Verastem Inc Stock (VSTM) Company Profile
Nome
Verastem Inc
Settore
Industria
Telefono
(781) 292-4200
Indirizzo
117 KENDRICK STREET, NEEDHAM, MA
Confronta VSTM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
5.68 | 252.80M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-31 | Reiterato | BTIG Research | Buy |
| 2024-09-30 | Iniziato | Guggenheim | Buy |
| 2023-11-21 | Ripresa | BTIG Research | Buy |
| 2023-09-27 | Iniziato | B. Riley Securities | Buy |
| 2023-06-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-07 | Ripresa | Alliance Global Partners | Buy |
| 2022-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-03-09 | Iniziato | Truist | Buy |
| 2021-07-01 | Iniziato | Alliance Global Partners | Buy |
| 2021-05-24 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2019-06-20 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Iniziato | BTIG Research | Buy |
| 2018-05-02 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-13 | Iniziato | Oppenheimer | Outperform |
| 2017-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2015-09-29 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2015-09-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Downgrade | Mizuho | Buy → Neutral |
| 2015-09-28 | Downgrade | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-05-12 | Reiterato | UBS | Buy |
| 2015-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2015-01-23 | Reiterato | ROTH Capital | Buy |
| 2014-07-08 | Ripresa | Oppenheimer | Perform |
| 2014-02-11 | Iniziato | Mizuho | Buy |
Mostra tutto
Verastem Inc Borsa (VSTM) Ultime notizie
Verastem Oncology Announces Multiple Data Presentations At Society Of Gynecologic Oncology 2025 Annual Meeting On Women's Cancer - Marketscreener.com
Can This New Ovarian Cancer Drug Transform Treatment? Key Data Reveals Breakthrough Potential - StockTitan
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag - MSN
When the Price of (VSTM) Talks, People Listen - Stock Traders Daily
Financial Snapshot: Analyzing Verastem Inc (VSTM)’s Key Ratio Metrics - The Dwinnex
Verastem Inc (NASDAQ: VSTM) Shares Fall By -4.77 Percent In The Past Week, But How Long Will It Last? - Marketing Sentinel
The time has not yet come to remove your chips from the table: Verastem Inc (VSTM) - SETE News
Recent Insider Activity Could Benefit Verastem Inc (VSTM) - Knox Daily
Verastem CEO Dan Paterson sells shares worth $4,890 - MSN
Verastem CEO Dan Paterson sells shares worth $4,890 By Investing.com - Investing.com Canada
Verastem, Inc. (NASDAQ:VSTM) Shares Acquired by JPMorgan Chase & Co. - Defense World
Verastem (NASDAQ:VSTM) Given New $9.00 Price Target at B. Riley - MarketBeat
Verastem, Inc. (NASDAQ:VSTM) Sees Large Increase in Short Interest - MarketBeat
Financial Metrics Check: Verastem Inc (VSTM)’s Ratios for Trailing Twelve Months - The Dwinnex
B. Riley Forecasts Strong Price Appreciation for Verastem (NASDAQ:VSTM) Stock - Defense World
Brokerages Set Verastem, Inc. (NASDAQ:VSTM) PT at $13.38 - MarketBeat
Vanguard Group Inc. Increases Stake in Verastem Inc. - GuruFocus.com
Verastem price target raised to $9 from $7 at B. Riley - MSN
B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating -January 31, 2025 at 09:19 am EST - Marketscreener.com
Verastem Licenses Investigational Cancer Drug VS-7375 from GenFleet, Shares Rise 4.1% – Market - HPBL
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference - Yahoo Finance
Verastem Exercises Option for VS-7375 Targeting RAS Pathway Driven CancersVerastem, Inc. (NASDAQ:VSTM) has announced the exercise of its option with regards to VS-7375, which is an oral and selective KRAS G12D (ON/OFF) inhibitor. This move signif - Defense World
Guggenheim Reiterates Buy Rating for Verastem (NASDAQ:VSTM) - Defense World
Verastem's (VSTM) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Mizuho maintains Verastem stock outperform with $9 target By Investing.com - Investing.com Australia
Mizuho maintains Verastem stock outperform with $9 target - MSN
Cantor Fitzgerald Estimates Verastem FY2025 Earnings - Defense World
Verastem Stock Soars 46% After FDA Grants Priority Review for Cancer Treatment – Market - HPBL
Cantor Fitzgerald Forecasts Verastem FY2025 Earnings - MarketBeat
Verstem avutometinib and defactinib combo gains FDA priority review - Seeking Alpha
Verastem Expands Oncology Pipeline with VS-7375 Acquisition - TipRanks
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
Barclays PLC Acquires 47,094 Shares of Verastem, Inc. (NASDAQ:VSTM) - MarketBeat
KRAS Inhibitors Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines - Barchart
Verastem appoints new COO with extensive biotech experience By Investing.com - Investing.com South Africa
Verastem appoints new COO with extensive biotech experience - Investing.com India
Verastem Appoints Matthew E. Ros as COO - TipRanks
Verastem Secures $150 Million Note Purchase Agreement with Oberland Capital - Defense World
Verastem Inc Azioni (VSTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Verastem Inc Azioni (VSTM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Paterson Dan | President and CEO |
Jan 13 '25 |
Sale |
5.24 |
8,568 |
44,896 |
347,581 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):